<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Perflutren lipid microspheres: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Perflutren lipid microspheres: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Perflutren lipid microspheres: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11823" href="/d/html/11823.html" rel="external">see "Perflutren lipid microspheres: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709204"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious cardiopulmonary reactions: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes perflutren administration. Always have resuscitation equipment and trained personnel readily available.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F208499"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Definity;</li>
<li>Definity RT</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912183"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Definity</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F208509"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F208501"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e87917f7-25b1-473a-abaa-b3eccb619cb2">Cardiovascular imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular imaging:</b> Dose should be given following baseline noncontrast echocardiography. Imaging should begin immediately following dose and compared to noncontrast image. Mechanical index for the ultrasound device should be set at ≤0.8.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV bolus:</b> 10 microliters (mcL)/kg of activated product, followed by 10 mL saline flush; may repeat in 30 minutes (followed by 10 mL saline flush) if needed (maximum dose per imaging study: 2 bolus doses).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV infusion:</b> Initial: 4 mL/minute (or 240 mL/hour) of prepared infusion; titrate to achieve optimal image up to a maximum of 10 mL/minute (or 600 mL/hour) (maximum dose per imaging study: 1 IV infusion).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="057eeeb8-c8ed-46f7-a02d-b9e8729b7ec9">Focal liver lesion evaluation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal liver lesion evaluation (off-label use): IV bolus:</b> 0.1 to 0.6 mL per injection followed by a 5 mL saline flush; may be repeated at a minimum of every 5 minutes (ie, when most microbubbles have vanished) up to a maximum total dose of 10 microliters (mcL)/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15256618','lexi-content-ref-18834687','lexi-content-ref-23137926','lexi-content-ref-17526609','lexi-content-ref-24529054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15256618','lexi-content-ref-18834687','lexi-content-ref-23137926','lexi-content-ref-17526609','lexi-content-ref-24529054'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991146"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988487"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F3062254"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F208479"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal pain (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain, ECG abnormality, hypertension, hypotension, palpitations, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, erythematous rash, pruritus, skin rash, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, dyspepsia, tongue disease, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, granulocytosis, hematoma, leukocytosis, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue, hypertonia, pain, paresthesia, rigors, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lower limb cramp</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea, hypoxia, pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, shock, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, coma, loss of consciousness, seizure, transient ischemic attacks, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory distress, stridor, wheezing</p></div>
<div class="block coi drugH1Div" id="F208489"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to perflutren or to any component of the formulation, including polyethylene glycol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Patients with known right-to-left, bi-directional, or transient right-to-left cardiac shunts; direct intra-arterial injection; within 24 hours prior to extracorporeal shock wave lithotripsy.</p></div>
<div class="block war drugH1Div" id="F208477"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Postmarketing reports of serious anaphylactoid reactions (eg, death, shock, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, palatal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Assess patients for prior hypersensitivity reactions to products containing polyethylene glycol (eg, certain colonoscopy bowel preparations and laxatives); increased risk of serious reactions may occur. Monitor for signs and symptoms of hypersensitivity reactions. Equipment for resuscitation and trained personnel should be readily available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious cardiopulmonary reactions: <b>[US Boxed Warning]: Serious cardiopulmonary reactions (including fatalities) have occurred during or following administration; most serious reactions occur within 30 minutes of administration. </b>
<b>Assess all patients for the presence of any condition that precludes administration. <b> Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.</b></b> Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary artery syndromes, worsening or unstable HF, serious ventricular arrhythmias). However, multiple retrospective and prospective studies involving the use of perflutren-based ultrasound contrast agents have suggested they may be safely used in patients with significant cardiopulmonary disease (ie, acute coronary syndromes, heart failure, COPD, pulmonary hypertension) or critical illness (Dolan 2009; Kurt 2009; Kusnetzky 2008; Main 2008; Main 2014; Nucifora 2008; Wei 2008; Wei 2012; Weiss 2012; Wever-Pinzon 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. Safety of activated perflutren lipid microspheres with mechanical indices &gt;0.8 or use of end-systolic triggering has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac shunts: Assess patients with cardiac shunts for embolic phenomena following administration; perflutren lipid microspheres can bypass filtering by the lung and enter the arterial circulation. Patients with small degrees of right-to-left shunting through patent foramen ovales (those that result in transient appearance of saline contrast in the left atrium or ventricle and do not fill the left atrial or LV cavity) are not considered at an increased risk for microvascular occlusion with perflutren-based ultrasound contrast agents (ASE [Porter 2014]); Kalra 2014; Muskula 2017; Parker 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease: Acute pain episodes, including moderate to severe back pain and vaso-occlusive crisis, have occurred in persons with sickle cell disease shortly after administration. Discontinue use if new or worsening pain occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Product must be activated prior to use. For IV administration only; do not administer by intra-arterial injection.</p></div>
<div class="block foc drugH1Div" id="F208484"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Definity: OFP 6.52 mg/mL and lipid blend 0.75 mg/mL (2 mL) [following activation, forms a suspension containing perflutren lipid microspheres 1.2 x 10<sup>10</sup>/mL and OFP 1.1 mg/mL]</p>
<p style="text-indent:-2em;margin-left:4em;">Definity RT: OFP 6.52 mg/mL and lipid bleng 3.75 mg/mL (2 mL) [following activation, forms a suspension containing a maximum of perflutren lipid microspheres 1.2 x 10<sup>10</sup>/mL and OFP 0.65 mg/mL]</p></div>
<div class="block geq drugH1Div" id="F208474"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323664"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Definity Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.52 mg/mL (per mL): $201.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Definity RT Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.52 mg/mL (per mL): $192.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F208486"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There are 2 different formulations of this product; one is a refrigerated product and one is a room temperature product. Make sure to follow correct procedures for the correct product.</p>
<p style="text-indent:-2em;margin-left:2em;">Refrigerated formulation (Definity):</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus (undiluted):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cardiovascular imaging:</i> Administer only after activation in the Vialmix or Vialmix RFID apparatus. Administer within 30 to 60 seconds of activation; follow each injection with a 10 mL saline flush.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Focal liver lesion evaluation (off-label use): </i>Administer only after activation in the Vialmix apparatus. Follow each injection with a 5 mL saline flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15256618','lexi-content-ref-18834687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15256618','lexi-content-ref-18834687'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus (diluted): Administer only after activation in the Vialmix or Vialmix RFID apparatus. Administer slowly up to 3 mL of solution; subsequent boluses of 1 to 2 mL may be used as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion rate: Initially, 4 mL/minute (or 240 mL/hour) up to 10 mL/minute (or 600 mL/hour); adjust flow rate for optimal image enhancement.</p>
<p style="text-indent:-2em;margin-left:2em;">Room temperature formulation (Definity RT):</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus (undiluted):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cardiovascular imaging:</i> Administer only after activation in the Vialmix RFID apparatus. Administer within 5 minutes of activation; follow each injection with a 10 mL saline flush.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Focal liver lesion evaluation (off-label use): </i>Administer only after activation in the Vialmix RFID apparatus. Follow each injection with a 5 mL saline flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15256618','lexi-content-ref-18834687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15256618','lexi-content-ref-18834687'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion rate: Initially, 4 mL/minute (or 240 mL/hour) up to 10 mL/minute (or 600 mL/hour); adjust flow rate for optimal image enhancement.</p></div>
<div class="block use drugH1Div" id="F208485"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cardiovascular imaging:</b> Opacification of the left ventricular chamber and improvement of delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms</p></div>
<div class="block off-label drugH1Div" id="F50548349"><span class="drugH1">Use: Off-Label: Adult</span><p>Focal liver lesion evaluation</p></div>
<div class="block mst drugH1Div" id="F27979373"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Perflutren lipid microspheres may be confused with influenza virus vaccine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299852"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222234"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F208491"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Due to the very short half-life, administration during pregnancy is not expected to result in clinically relevant fetal exposure.</p></div>
<div class="block brc drugH1Div" id="F20617601"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if perflutren lipid microspheres is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The very short half-life should limit exposure to breast milk.</p></div>
<div class="block mop drugH1Div" id="F6188463"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiopulmonary reactions (rare); signs and symptoms of anaphylactoid reactions (rare). Monitor patient as appropriate based upon patient clinical disposition; specific monitoring parameters based upon perflutren lipid microspheres administration are not necessary (Muskula 2017).</p></div>
<div class="block pha drugH1Div" id="F208476"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Activated perflutren lipid microspheres provide contrast enhancement of the endocardial borders during echocardiography.</p></div>
<div class="block phk drugH1Div" id="F208488"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Immediate</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: IV bolus: 3.4 minutes; IV infusion: 7.1 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Octafluoropropane gas (OFP): Not metabolized; Phospholipid component: Metabolized to free fatty acids </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: OFP: 1.3 minutes (healthy patients); 1.9 minutes (patients with COPD)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F208492"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Luminity</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Luminity</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Luminity</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Definity</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Luminity</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Definity</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15256618">
<a name="15256618"></a>Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. <i>Radiographics.</i> 2004;24(4):921-935. doi:10.1148/rg.244035158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/15256618/pubmed" id="15256618" target="_blank">15256618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137926">
<a name="23137926"></a>Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. <i>Ultrasound Med Biol.</i> 2013;39(2):187-210. doi:10.1016/j.ultrasmedbio.2012.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/23137926/pubmed" id="23137926" target="_blank">23137926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantheus.1">
<a name="Lantheus.1"></a>Definity (perflutren lipid microspheres) [prescribing information]. North Billerica, MA: Lantheus Medical Imaging; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantheus.2">
<a name="Lantheus.2"></a>Definity (perflutren lipid microspheres) [product monograph]. Montreal, Quebec, Canada: Lantheus Medical Imaging Canada; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantheus.3">
<a name="Lantheus.3"></a>Definity RT (perflutren lipid microspheres) [prescribing information]. North Billerica, MA: Lantheus Medical Imaging; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantheus.4">
<a name="Lantheus.4"></a>Definity RT (perflutren lipid microspheres) [prescribing information]. North Billerica, MA: Lantheus Medical Imaging; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19118722">
<a name="19118722"></a>Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. <i>J Am Coll Cardiol.</i> 2009;53(1):32-38. doi:10.1016/j.jacc.2008.08.066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19118722/pubmed" id="19118722" target="_blank">19118722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460662">
<a name="18460662"></a>Herzog CA. Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography. <i>JAMA. </i>2008;299(17):2023-2025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18460662/pubmed" id="18460662" target="_blank">18460662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18834687">
<a name="18834687"></a>Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. <i>Eur J Radiol.</i> 2009;72(3):418-424. doi:10.1016/j.ejrad.2008.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18834687/pubmed" id="18834687" target="_blank">18834687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24524748">
<a name="24524748"></a>Kalra A, Shroff GR, Erlien D, et al. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts. <i>JACC Cardiovasc Imaging.</i> 2014;7(2):206-207. doi:10.1016/j.jcmg.2013.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24524748/pubmed" id="24524748" target="_blank">24524748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19245974">
<a name="19245974"></a>Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. <i>J Am Coll Cardiol.</i> 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19245974/pubmed" id="19245974" target="_blank">19245974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18436124">
<a name="18436124"></a>Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. <i>J Am Coll Cardiol.</i> 2008;51(17):1704-1706. doi:10.1016/j.jacc.2008.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18436124/pubmed" id="18436124" target="_blank">18436124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19064035">
<a name="19064035"></a>Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). <i>Am J Cardiol.</i> 2008;102(12):1742-1746. doi:10.1016/j.amjcard.2008.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/19064035/pubmed" id="19064035" target="_blank">19064035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290568">
<a name="24290568"></a>Main ML, Hibberd MG, Ryan A, et al. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. <i>JACC Cardiovasc Imaging.</i> 2014;7(1):40-48. doi:10.1016/j.jcmg.2013.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24290568/pubmed" id="24290568" target="_blank">24290568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377467">
<a name="28377467"></a>Muskula PR, Main ML. Safety with echocardiographic contrast agents. <i>Circ Cardiovascular Imaging.</i> 2017;10(4):pii: e005459. doi:10.1161/CIRCIMAGING.116.005459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/28377467/pubmed" id="28377467" target="_blank">28377467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18635517">
<a name="18635517"></a>Nucifora G, Marsan NA, Siebelink HM, et al. Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction. <i>Eur J Echocardiogr.</i> 2008;9(6):816-818. doi:10.1093/ejechocard/jen167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18635517/pubmed" id="18635517" target="_blank">18635517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816393">
<a name="23816393"></a>Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.<i> Am J Cardiol.</i> 2013;112(7):1039-1045. doi:10.1016/j.amjcard.2013.05.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/23816393/pubmed" id="23816393" target="_blank">23816393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085408">
<a name="25085408"></a>Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography.<i> J Am Soc Echocardiogr.</i> 2014;27(8):797-810. doi:10.1016/j.echo.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/25085408/pubmed" id="25085408" target="_blank">25085408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18848430">
<a name="18848430"></a>Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. <i>J Am Soc Echocardiogr.</i> 2008;21(11):1202-1206. doi:10.1016/j.echo.2008.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/18848430/pubmed" id="18848430" target="_blank">18848430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22365709">
<a name="22365709"></a>Wei K, Main ML, Lang RM, et al. The effect of Definity on systemic and pulmonary hemodynamics in patients. <i>J Am Soc Echocardiogr.</i> 2012;25(5):584-588. doi:10.1016/j.echo.2012.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22365709/pubmed" id="22365709" target="_blank">22365709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22560734">
<a name="22560734"></a>Weiss RJ, Ahmad M, Villanueva F, et al. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice. <i>J Am Soc Echocardiogr.</i> 2012;25(7):790-795. doi:10.1016/j.echo.2012.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22560734/pubmed" id="22560734" target="_blank">22560734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22427401">
<a name="22427401"></a>Wever-Pinzon O, Suma V, Ahuja A, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study. <i>Eur Heart J Cardiovasc Imaging.</i> 2012;13(10):857-862. doi:10.1093/ehjci/jes057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/22427401/pubmed" id="22427401" target="_blank">22427401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17526609">
<a name="17526609"></a>Wilson SR, Jang HJ, Kim TK, et al. Diagnosis of focal liver masses on ultrasonography: comparison of unenhanced and contrast-enhanced scans. <i>J Ultrasound Med.</i> 2007;26(6):775-787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/17526609/pubmed" id="17526609" target="_blank">17526609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529054">
<a name="24529054"></a>Won SY, Singh N, Lim BG, et al. Hepatic contrast-enhanced ultrasound: impact of its introduction in the Australian context.<i> J Med Imaging Radiat Oncol.</i> 2014;58(1):38-45. doi:10.1111/1754-9485.12093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/perflutren-lipid-microspheres-drug-information/abstract-text/24529054/pubmed" id="24529054" target="_blank">24529054</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10142 Version 149.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
